Finerenone
Brand name: Kerendia
Rank #175 of 500 drugs by total cost
$89.5M
Total Cost
93,151
Total Claims
$89.5M
Total Cost
2,529
Prescribers
$961
Cost per Claim
12,377
Beneficiaries
137,116
30-Day Fills
$35K
Avg Cost/Provider
37
Avg Claims/Provider
About Finerenone
Finerenone (sold as Kerendia) was prescribed 93,151 times by 2,529 Medicare Part D providers in 2023, costing the program $89.5M. At $961 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 172 | Ribociclib Succinate (Kisqali) | $90.3M | 5,978 |
| 173 | Lacosamide (Lacosamide) | $90.1M | 300,038 |
| 174 | Mepolizumab (Nucala) | $90.1M | 20,798 |
| 175 | Finerenone (Kerendia) | $89.5M | 93,151 |
| 176 | Ixazomib Citrate (Ninlaro) | $89.0M | 6,901 |
| 177 | Lamotrigine (Lamotrigine) | $89.0M | 1,603,798 |
| 178 | Insulin Aspart Prot/Insuln Asp (Novolog Mix 70-30 Flexpen) | $88.8M | 79,814 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology